These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

902 related items for PubMed ID: 19624076

  • 1. Evolving modalities for femoropopliteal interventions.
    Ansel GM, Lumsden AB.
    J Endovasc Ther; 2009 Apr; 16(2 Suppl 2):II82-97. PubMed ID: 19624076
    [Abstract] [Full Text] [Related]

  • 2. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.
    Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM, VIBRANT Investigators.
    J Vasc Surg; 2013 Aug; 58(2):386-95.e4. PubMed ID: 23676191
    [Abstract] [Full Text] [Related]

  • 3. New stents for SFA.
    MINAR E, SCHILLINGER M.
    J Cardiovasc Surg (Torino); 2009 Oct; 50(5):635-45. PubMed ID: 19741579
    [Abstract] [Full Text] [Related]

  • 4. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
    Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschorner U, Kultgen PL, Rastan A.
    JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Primary nitinol stenting for femoropopliteal disease.
    Mewissen MW.
    J Endovasc Ther; 2009 Apr; 16(2 Suppl 2):II63-81. PubMed ID: 19624075
    [Abstract] [Full Text] [Related]

  • 7. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
    Antoniou GA, Georgakarakos EI, Antoniou SA, Georgiadis GS.
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
    [Abstract] [Full Text] [Related]

  • 8. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Ristl R, Schoder M.
    J Am Coll Cardiol; 2013 Oct 08; 62(15):1320-7. PubMed ID: 23831445
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K, Ullery BW, Kret MR, Lee JT.
    Ann Vasc Surg; 2017 Jan 08; 38():90-98. PubMed ID: 27554688
    [Abstract] [Full Text] [Related]

  • 11. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K, Gable D, Pearl G, Theune B, Black S.
    J Vasc Surg; 2010 Sep 08; 52(3):584-90; discussion 590-1, 591.e1-591.e7. PubMed ID: 20598480
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
    Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M.
    J Vasc Surg; 2010 Sep 08; 52(3):608-15. PubMed ID: 20573476
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
    Tsujimura T, Takahara M, Iida O, Soga Y, Katsuki T, Fujihara M, Kawasaki D, Kozuki A, Mano T.
    J Vasc Surg; 2021 Jun 08; 73(6):1998-2008.e1. PubMed ID: 33347998
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
    Gouëffic Y, Kaladji A, Guyomarch B, Montagne C, Fairier D, Gestin S, Riche VP, Vent PA, Chaillou P, Costargent A, Patra P.
    Trials; 2014 Oct 30; 15():423. PubMed ID: 25359394
    [Abstract] [Full Text] [Related]

  • 18. Comparison of drug-eluting balloon angioplasty with self-expanding interwoven nitinol stent deployment in patients with complex femoropopliteal lesions.
    Teymen B, Akturk S, Akturk U, Tdjani M.
    Vascular; 2018 Feb 30; 26(1):54-61. PubMed ID: 28708023
    [Abstract] [Full Text] [Related]

  • 19. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.
    Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Cao AY, Jaff MR, RESILIENT Investigators.
    J Endovasc Ther; 2012 Feb 30; 19(1):1-9. PubMed ID: 22313193
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of femoropopliteal artery drug-eluting balloons and drug-eluting stents (FOREST trial): Study protocol for a randomized controlled trial.
    Jongsma H, van Mierlo-van den Broek P, Imani F, van den Heuvel D, de Vries JPM, Fioole B.
    J Vasc Surg; 2017 Oct 30; 66(4):1293-1298. PubMed ID: 28826727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.